Knight Therapeutics Inc.
TSX:GUD.TO · Toronto Stock Exchange
+$0.07 today
Vol 0.04M · Avg 0.10M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
TSX:GUD.TO · Revenue to Net Income
Key Ratios
Analysis
$510.5M of revenue converted into $5.6M of net income for the selected period. Gross margin is 37.5% and net margin is 0.2%, showing how much revenue survives after costs and taxes. EPS is $0.05, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $450.1M +21.2% | $371.3M +13.1% | $328.2M +11.8% | $293.6M +20.6% | $243.5M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $299.3M +52.0% | $196.9M +12.2% | $175.5M +12.9% | $155.5M +21.4% | $128.1M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $150.7M -13.6% | $174.4M +14.3% | $152.7M +10.6% | $138.1M +19.6% | $115.4M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 33.5% -13.5pp | 47.0% +0.5pp | 46.5% -0.5pp | 47.0% -0.4pp | 47.4% | 9.8% | 28.9% | 38.3% |
| Research & Development | $29.0M +24.4% | $23.3M +32.8% | $17.5M +18.9% | $14.8M +16.3% | $12.7M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $124.0M +24.8% | $99.3M +18.7% | $83.7M -5.6% | $88.6M +19.2% | $74.4M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $152.9M -8.4% | $167.0M +7.4% | $155.5M +0.3% | $155.1M +21.0% | $128.2M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $56.6M +6.5% | $53.1M +5.4% | $50.4M -19.5% | $62.6M +30.7% | $47.9M | $374.2M | $1.2B | $631.8M |
| EBITDA | $54.4M -15.6% | $64.4M +57.4% | $40.9M +61.9% | $25.3M -40.7% | $42.6M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 12.1% -5.3pp | 17.3% +4.9pp | 12.5% +3.9pp | 8.6% -8.9pp | 17.5% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$2.2M -129.8% | $7.4M +356.0% | -$2.9M -20.3% | -$2.4M +54.8% | -$5.3M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -0.5% -2.5pp | 2.0% +2.9pp | -0.9% -0.1pp | -0.8% +1.4pp | -2.2% | 16.6% | 24.1% | 22.0% |
| Interest Income | $6.2M -40.4% | $10.4M -17.2% | $12.6M +18.3% | $10.6M +44.0% | $7.4M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $10.4M +13.0% | $9.2M -26.1% | $12.5M +89.2% | $6.6M +82.4% | $3.6M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$4.5M +15.8% | -$5.3M +72.0% | -$19.1M -554.9% | -$2.9M -114.9% | $19.5M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$6.7M -426.6% | $2.1M +109.3% | -$22.0M +50.0% | -$44.0M -757.1% | $6.7M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -1.5% -2.0pp | 0.6% +7.3pp | -6.7% +8.3pp | -15.0% -17.7pp | 2.7% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | -$1.3M +41.8% | -$2.3M +55.8% | -$5.2M +63.4% | -$14.1M -56.6% | -$9.0M | $1.3B | -$1.6B | $745.2M |
| Net Income | -$5.4M -224.1% | $4.3M +125.7% | -$16.8M +43.7% | -$29.9M -290.7% | $15.7M | $4.9B | $4.8B | $4.7B |
| Net Margin | -1.2% -2.4pp | 1.2% +6.3pp | -5.1% +5.1pp | -10.2% -16.6pp | 6.4% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$0 -226.2% | $0 +126.8% | -$0 +38.5% | -$0 -300.0% | $0 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$0 -226.2% | $0 +126.8% | -$0 +38.5% | -$0 -300.0% | $0 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $99.6M -1.5% | $101.0M -6.0% | $107.5M -6.5% | $114.9M -7.7% | $124.5M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $99.6M -1.8% | $101.4M -5.6% | $107.5M -6.5% | $114.9M -7.7% | $124.5M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Bright Minds Biosciences Inc.
DRUG.CN
$650.96M
Kneat.com, Inc.
TSX:KSI.TO
$618.13M
Verano Holdings Corp.
VRNO.NE
$594.30M
Vitalhub Corp.
TSX:VHI.TO
$453.89M
Cipher Pharmaceuticals Inc.
TSX:CPH.TO
$408.04M
Cresco Labs Inc.
CL.CN
$407.36M
TerrAscend Corp.
TSX:TSND.TO
$284.80M
Canopy Growth Corporation
TSX:WEED.TO
$244.44M
Aurora Cannabis Inc.
TSX:ACB.TO
$234.78M
OrganiGram Holdings Inc.
TSX:OGI.TO
$189.01M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does GUD.TO generate?
Knight Therapeutics Inc. (GUD.TO) reported $450.09M of revenue in fiscal 2025.
Is GUD.TO profitable?
Knight Therapeutics Inc. (GUD.TO) reported -$5,374,000.00 of net income, with a net margin of -1.2%.
Explore More
Continue the stock analysis
Jump to another research area for this company.